Background
==========

Soft tissue sarcomas (STS) are heterogeneous malignancies originating from the mesenchymal lineage. There are more than 50 different histological entities and they comprise less than 1% of adult malignancies \[[@B1]\]. The STS are among the most aggressive cancer types with a lethality of 40--50% due to metastasis or local relapse \[[@B2]\]. There are several prognostic factors which determine tumor progression, and ultimately the patient's outcome, including positive resection margins, presence of local recurrence, histological entity and tumor grade, size, location and depth \[[@B3]-[@B9]\].

Many studies have been designed to investigate the prognostic factors of STS by using immunohistochemical methods \[[@B10]\], and most of the published data have focused on the expression of markers for cell kinetics and regulatory proteins of the cell cycle.

Immunotherapy and vaccines with the capability to activate the host immune system may have a role as second-line therapy, and characterization of the in situ cellular and molecular immunology form the basis for such therapy \[[@B11]\]. Hence, clinical data on the prognostic significance of different immunological cells are warranted.

The innate immune system consists mainly of granulocytes, macrophages, natural killer (NK) cells, dendritic cells (DCs) and their corresponding growth factors and receptors \[[@B12]\]. They mediate major histocompatibility complex unrestricted cytotoxicity and are essential in the immediate limitation and elimination of foreign challenges to the host, including defense against cancer, but lack the ability of 'memory' when re-exposed to the same antigen\[[@B12],[@B13]\]. The NK cell has a well-established role in tumor rejection in a variety of cancers\[[@B14]-[@B16]\], and the mechanism by which these cells discriminate tumor from normal cells has provided new insights into tumor immunosurveillance and has suggested new strategies in the treatment of human cancer \[[@B17],[@B18]\].

Ki67 expression increases with increasing malignancy grade in many cancer types of different lineages \[[@B19]-[@B23]\]. In Ewing's sarcoma, high Ki67 expression was an independent prognostic factor for progression free survival and overall survival independent of treatment type \[[@B24]\].

We have previously reported the prognostic significance of the humoral immune system by lymphocyte infiltration in tumor \[[@B25]\] and peritumoral capsule \[[@B26]\] of STS. We have also reported the significance of the innate immune system by the correlation of expression of macrophages (CD68), their growth factor macrophage colony-stimulating factor (M-CSF), its receptor colony-stimulating factor-1 receptor (CSF-1R) and histological grade in STS \[[@B27]\]. It was important to validate these findings in a different material, explore the relationship to expression of Ki67, disease-specific survival (DSS) and include other markers as CD57 and TGF-beta. The purpose of this study was to examine the prognostic role of the innate immune system in STS by assessing the expression of CD68, M-CSF, CSF-1R, CD57, TGF-beta and Ki67.

Methods
=======

Patients and clinical samples
-----------------------------

The National Cancer Data Inspection Board and The Regional Committee for Research Ethics approved the study. The material was collected from our approved biobank for paraffin embedded material and slides. Data were analyzed anonymously.

Primary tumor tissue from untreated patients diagnosed with STS at the University Hospital of North Norway (UNN) from 1973 to 2006 and the Hospitals of Arkhangelsk region, Russia, from 1996 to 2006 was used in this retrospective study. 496 potentially suitable patient records were identified from the hospital database, but only 249 of these were eligible based on complete medical records and adequate paraffin-embedded tissue blocks. In 80 of these cases it was also possible to obtain tissue from the peritumoral capsule for TMA \[[@B26]\]. This report includes follow-up data for 167 Norwegian and 82 Russian patients until September 2009. The median follow-up was 38 (range 0--392) months.

The histology of all soft tissue sarcoma cases was reviewed according to modern classification (WHO, 2002) by two dedicated pathologists (AV and SWS). For the Russian material, new slides were made from all paraffin blocks. For the Norwegian material, new slides were made when necessary. All biopsies were immunostained with cytokeratin (CK), c-kit (CD117), Actin, smooth muscle actin (SMA), vimentin (VIM) and CD34. Some slides were also stained with S100 if necessary to rule out differential diagnoses. Further molecular methods were, in general, not considered necessary for differential diagnostics, but in some cases PCR or FISH were performed. About 10% of the initial diagnoses were revised due to altered classification and the appearance of new entities such as GIST. All carcinosarcomas, endometrial sarcomas, carcinomas and lymphomas were excluded.

Microarray construction
-----------------------

Tissue microarrays (TMAs) were constructed for high-throughput molecular pathology research\[[@B28]-[@B30]\]. The slides were evaluated by two pathologists (AV and SWS) using light microscope to identify the tumor and the peritumoral capsule. The most representative areas of the tumor and peritumoral capsule were carefully selected and marked on the hematoxylin and eosin (HE) slides for the corresponding donor blocks and sampled for the tissue microarray collector blocks\[[@B26]\]. The TMAs were assembled using a tissue-arraying instrument (Beecher Instruments).

Studies suggest that punching multiple 0.6 mm cores from different regions captures the heterogeneity of the capsule more accurately than single 2 to 4 mm cores \[[@B30]\]. Hence, we obtained two 0.6-mm cores of tumor and two cores from peritumoral capsule (four cores from each patient). These were secured from different representative areas of the tissue block and selected to be as representative as possible. To include all core samples, 12 tissue array blocks were constructed. Multiple 4-μm sections were cut with a Micron microtome (HM355S) and specific antibodies were stained for immunohistochemistry (IHC).

Immunohistochemistry (IHC)
--------------------------

Sections were deparaffinized with xylene and rehydrated with ethanol. Antigen retrieval was performed by placing the specimens in 0.01 M citrate buffer at pH 6.0 and exposing them to two repeated microwave heatings of 10 min at 450 W. The slides were then transferred to the Ventana Benchmark, XT automated slide stainer (Ventana Medical System, Illkirch, France). Tissue sections were incubated with primary mouse monoclonal antibodies recognizing Ki67, CD68 and CD57 (Ventana Medical System), as well as rabbit polyclonal M-CSF, CSF-1R (clone H-300; Santa Cruz Biotechnology, Santa Cruz, CA, USA) and TGF-beta (clone sc-146; Santa Cruz). The dilution was 1:5 for M-CSF, 1:25 for CSF-1R and 1:50 for TGF-beta. All Ventana antibodies were prediluted by the manufacturer. The incubation periods were 16 min for Ki67, CD57 and CD68, and 28 min for TGF-beta, M-CSF and CSF-1R. As secondary antibodies, biotinylated goat antimouse IgG and mouse antirabbit IgM, both 200 lg ml, were used. The Dako EnVision + System-Horseradish Peroxidase \[diaminobenzidine (DAB)\] kit (Dako, Glostrup, Denmark) was used to block endogenous peroxidase. This was followed by application of liquid diaminobenzidine as substrate-chromogen, yielding a brown reaction product at the site of the target antigen (iView DAB® procedure). Finally, slides were counterstained with hematoxylin to visualize the nuclei. For each antibody, including controls, all TMA staining were performed in a single experiment. As negative staining controls, the primary antibodies were replaced with the primary antibody diluents. In the TMA we also used cores from carcinomas and normal tissue as positive and negative controls.

Scoring of IHC
--------------

The ARIOL imaging system (Genetix, San Jose, CA) was used to scan the slides for antibody staining of the TMAs\[[@B26]\]. The number of CD57 positive cells (including NK cells) and CD68 positive cells (including macrophages) in tumors were scored as 0 (no cells), 1 (1--5 cells), 2 (6--19) or 3 (20+ cells) per 0.6 mm core. Examples are shown in Figure [1](#F1){ref-type="fig"}. Regarding M-CSF, CSF-1R, Ki67 and TGF-beta, expression was scored as: 0, negative; 1, weak; 2, intermediate; and 3, strong. The mean score from the duplicate cores from tumor or capsule, respectively, was used. Marker expression was dichotomised (low vs. high), and high expression defined as mean score ≥ 0.30 for CD68, ≥ 0.75 for TGF-beta, ≥ 2.00 for Ki67 and ≥ 0.01 for CD57, M-CSF and CSF-1R. All samples were anonymized and independently scored by two pathologists (AV and SWS). When disagreement, the slides were re-examined and consensus was reached by the observers. When assessing a variable for a given score, the scores of the other variables and the outcome were hidden from the observers.

![**IHC microscopic pictures of TMA of soft tissue sarcoma representing different expression of CD68 and M-CSF.** (A) CD68 low expression; (B) CD68 high expression; (C) M-CSF low expression; (D) M-CSF high expression. Original magnification X 100 and 400.](1472-6890-12-7-1){#F1}

Statistical methods
-------------------

All statistical analyses were done using the statistical package SPSS (Chicago, IL), version 18. The immunohistochemistry scores from each observer were compared for interobserver reliability by use of a two-way random effect model with absolute agreement definition. The intraclass correlation coefficient (reliability coefficient) was obtained from these results.

The Chi-square test and Fishers Exact test were used to examine the association between molecular marker expression and various clinicopathological variables. Univariate analyses were performed using the Kaplan-Meier method, and statistical significance between survival curves was assessed by the log rank test. Disease-specific survival (DSS) was determined from the date of confirmed STS diagnosis.

The multivariate analysis was carried out using the Cox proportional hazards model to assess the independent impact of each pre-treatment variable on survival in the presence of other variables. Only significant variables from the univariate analyses were entered into the Cox regression analysis. Probability for stepwise entry and removal was set at 0.05 and 0.10, respectively. The significance level used was p \< 0.05.

Results
=======

Clinicopathological variables
-----------------------------

Demographic, clinical, and histopathological variables are shown in Table [1](#T1){ref-type="table"}. Patient age range was 0--91 years (mean 55 years), and 44% of the patients were males. The non-GIST STS comprised 68 undifferentiated pleomorphic sarcoma, 67 leiomyosarcoma, 34 liposarcoma, 20 malignant fibroblastic/myofibroblastic tumors, 16 rhabdomyosarcoma, 16 synovial sarcoma, 13 angiosarcoma, 11 malignant peripheral nerve sheath tumors (MPNST) and 4 other STS. There were 61 low grade STS (24%) and 188 high grade (FNCLCC grade 2 and 3) STS (76%).

###### 

Prognostic clinicopathological variables as predictors for disease-specific survival soft tissue sarcomas (univariate analysis, log rank test), N = 249

  ----------------------------------------------------------------------------------------------------------------------------------------------
  **Characteristic**                    **Patients (n)**   **Patients (%)**   **Median survival (months)**   **5-Year survival (%)**   **P**
  ------------------------------------- ------------------ ------------------ ------------------------------ ------------------------- ---------
  **Age**                                                                                                                               

   ≤ 20 years                           20                 8                  15                             40                        0.126

   21-60 years                          113                45                 68                             52                         

   \> 60 years                          116                47                 30                             40                         

  **Gender**                                                                                                                            

   Male                                 110                44                 41                             46                        0.390

   Female                               139                56                 45                             45                         

  **Nationality**                                                                                                                       

   Norwegian                            167                67                 63                             51                        0.011

   Russian                              82                 33                 22                             34                         

  **Histology**                                                                                                                         

   Undifferentiated\                    68                 27                 29                             40                        0.102
   pleomorphic sarcoma                                                                                                                 

   Leiomyosarcoma                       67                 27                 45                             46                         

   Liposarcoma                          34                 14                 NR                             67                         

   MF/MFT                               20                 8                  43                             50                         

   Angiosarcoma                         13                 5                  10                             31                         

   Rhabdomyosarcoma                     16                 6                  17                             38                         

   MPNST                                11                 4                  49                             45                         

   Synovial sarcoma                     16                 6                  31                             29                         

   Other STS                            4                  2                  NR                             75                         

  **Tumor localization**                                                                                                                

   Extremities                          89                 36                 100                            53                        0.348

   Trunk                                47                 29                 32                             44                         

   Retroperitoneum                      37                 25                 25                             38                         

   Head/Neck                            18                 7                  15                             41                         

   Visceral                             58                 23                 30                             42                         

  **Tumor size**                                                                                                                        

   \< 5 cm                              74                 30                 127                            57                        0.027

   5-10 cm                              91                 37                 44                             45                         

   \> 10 cm                             81                 32                 28                             37                         

   Missing                              3                  1                                                                            

  **Malignancy grade FNCLCC**                                                                                                           

   1                                    61                 25                 NR                             74                        \<0.001

   2                                    98                 39                 41                             45                         

   3                                    90                 36                 16                             26                         

  **Tumor depth**                                                                                                                       

   Superficial                          17                 7                  NR                             93                        \<0.001

   Deep                                 232                93                 36                             42                         

  **Metastasis at time of diagnosis**                                                                                                  

   No                                   206                83                 76                             53                        \<0.001

   Yes                                  43                 17                 10                             10                         

  **Surgery**                                                                                                                           

   Yes                                  228                92                 59                             50                        \<0.001

   No                                   21                 8                  5                              0                          

  **Surgical margins**                                                                                                                  

   Wide                                 108                43                 NR                             62                        \<0.001

   Non-wide                             141                57                 19                             33                         

  **Chemotherapy**                                                                                                                      

   No                                   191                77                 52                             47                        0.424

   Yes                                  58                 23                 29                             40                         

  **Radiotherapy**                                                                                                                      

   No                                   176                71                 48                             46                        0.590

   Yes                                  73                 29                 38                             43                         
  ----------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: MF/MFT, malignant fibroblastic/myofibroblastic tumors; MPNST, malignant peripheral nerve sheath tumor; STS, soft tissue sarcomas; NR, not reached; NOS, non specified.

The treatment option of choice was surgery (n = 228), seven patients received chemotherapy and/or radiotherapy only, and 14 patients received no therapy. A total of 120 patients received surgery only, 55 surgery and radiotherapy; 40 surgery and chemotherapy and 13 surgery, radiotherapy and chemotherapy. Two patients received chemotherapy only, three both chemotherapy and radiotherapy, and two radiotherapy only. The 5-year survival with non-wide resection margins was 33% and with wide resection margins 62%.

Inter-observer variability
--------------------------

There was good reproducibility between the two investigating pathologists. The scoring agreement was tested for M-CSF and CD68 expression in tumor. The IHC scores from each observer were compared using a two-way random effect model with absolute agreement definition. The intraclass correlation coefficients (reliability coefficients, r) obtained from these results were 0.85 for M-CSF (P \< 0.001) and 0.90 for CD68 (P \< 0.001).

Univariate analyses
-------------------

Nationality, tumor size, malignancy grade, tumor depth, metastasis at time of diagnosis, surgery and surgical margins were all significant indicators for disease-specific survival (DSS) in univariate analyses (Table [1](#T1){ref-type="table"}).

Besides, increased expression of M-CSF (P = 0.034), Ki67 (P \< 0.001) and TGF-beta (p = 0.003) in tumor correlated significantly with a shorter DSS, (Table [2](#T2){ref-type="table"} and Figure [2](#F2){ref-type="fig"}). Co-expression of M-CSF and TGF-beta (p = 0.004) also correlated with shorter DSS. No such relationship was observed for CD57, CD68, and CSR-1R.

###### 

Expression of markers in tumor and their prediction for disease-specific survival in patients with soft tissue sarcomas (univariate analysis; log-rank test), N = 249

  **Marker expression**    **Patients (n)**   **Patients (%)**   **Median survival (months)**   **5-Year survival (%)**   **P**
  ------------------------ ------------------ ------------------ ------------------------------ ------------------------- ---------
  **CD 57**                                                                                                                
   Low                     93                 37                 54                             49                        0.617
   High                    135                54                 49                             48                         
   Missing                 21                 8                                                                            
  **CD 68**                                                                                                                
   Low                     57                 23                 91                             52                        0.270
   High                    172                69                 45                             47                         
   Missing                 20                 8                                                                            
  **M-CSF**                                                                                                                
   Low                     56                 22                 NR                             59                        0.034
   High                    169                68                 38                             44                         
   Missing                 24                 10                                                                           
  **CSF-1R**                                                                                                               
   Low                     38                 15                 41                             44                        0.832
   High                    191                77                 38                             46                         
   Missing                 20                 8                                                                            
  **Ki67**                                                                                                                 
   Low                     31                 12                 NR                             63                        \<0.001
   Medium                  63                 25                 NR                             59                         
   High                    139                56                 24                             37                         
   Missing                 16                 6                                                                            
  **TGF-beta**                                                                                                             
   Low                     117                47                 99                             53                        0.003
   High                    122                49                 29                             37                         
   Missing                 10                 4                                                                            
  **M-CSF and TGF-beta**                                                                                                   
   Low                     119                48                 91                             53                        0.004
   High                    101                41                 29                             38                         
   Missing                 29                 12                                                                           

Abbreviations: NR, not reached.

![Disease-specific survival curves for high and low expression of CD68, Ki67, M-CSF, TGF-beta and co-expression M-CSF and TGF-beta in tumor in patients with STS (N = 249).](1472-6890-12-7-2){#F2}

A shorter DSS with increased expression of M-CSF was seen in females (P = 0.025), Norwegian patients (P = 0.015) and in patients with tumors larger than 5 cm (P = 0.018, data not shown).

Increased expression of Ki67 in the peritumoral capsule correlated with a shorter DSS (N = 80, P \< 0.001). Increased expression of CD68 in the peritumoral capsule tended to correlate with a shorter DSS, though not statistically significant (N = 80, P = 0.057), Table [3](#T3){ref-type="table"}. No prognostic impact was observed for CD57, M-CSF, CSR-1R, TGF-beta or co-expression of M-CSF and TGF-beta. There was a correlation of expression of Ki67 in tumor (N = 249, P = 0.001) and metastasis at the time of the diagnosis, but not no correlation of expression of Ki67 in peritumoral capsule (N = 80, P = 0.395) and metastasis at the time of the diagnosis (data not shown).

###### 

Expression of markers in peritumoral capsule and their prediction for disease-specific survival in patients with soft tissue sarcomas (univariate analysis; log-rank test), N = 80

  **Marker expression**    **Patients (n)**   **Patients (%)**   **Median survival (months)**   **5-Year survival (%)**   **P**
  ------------------------ ------------------ ------------------ ------------------------------ ------------------------- ---------
  **CD 57**                                                                                                                
   Low                     50                 63                 38                             47                        0.797
   High                    29                 36                 123                            55                         
   Missing                 1                  1                                                                            
  **CD 68**                                                                                                                
   Low                     34                 43                 NR                             61                        0.057
   High                    45                 56                 31                             43                         
   Missing                 1                  1                                                                            
  **M-CSF**                                                                                                                
   Low                     36                 45                 75                             54                        0.608
   High                    39                 49                 36                             46                         
   Missing                 5                  6                                                                            
  **CSF-1R**                                                                                                               
   Low                     36                 45                 52                             49                        0.587
   High                    37                 46                 57                             47                         
   Missing                 7                  9                                                                            
  **Ki67**                                                                                                                 
   Low                     32                 40                 NR                             74                        \<0.001
   High                    37                 46                 29                             35                         
   Missing                 11                 14                                                                           
  **TGF-beta**                                                                                                             
   Low                     43                 54                 52                             50                        0.906
   High                    28                 35                 31                             50                         
   Missing                 9                  11                                                                           
  **M-CSF and TGF-beta**                                                                                                   
   Low                     24                 30                 80                             57                        0.626
   High                    42                 53                 31                             45                         
   Missing                 14                 18                                                                           

Abbreviations: NR, not reached**.**

In co-variation analyses between malignancy grade and expression of the different markers in tumor, Ki67, CD68, M-CSF and TGF-beta showed statistical significance (data not shown). Increased expression of CD68 in tumor correlated with malignancy grade (P = 0.016) and expression of Ki67 (P \< 0.001). Increased expression of M-CSF in tumor correlated with malignancy grade (P = 0.010) and expression of Ki67 (P = 0.002). Increased expression of TGF-beta in tumor correlated with malignancy grade (P = 0.029) and expression of Ki67 (P = 0.005), table [4](#T4){ref-type="table"} and [5](#T5){ref-type="table"}. There was a co-variation between expression of M-CSF and TGF-beta in tumor (P \< 0.001, data not shown). In crosstabulation the expected count in the low M-CSF, high TGF-beta group was 26.7 patients (data not shown), but the observed count was 12 patients (Figure [2](#F2){ref-type="fig"}).

###### 

Results of expression of CD68 and M-CSF in tumor versus malignancy grade in patients with soft tissue sarcomas, N = 249

  **Expression**   **Malignancy grade (%)**                           
  ---------------- -------------------------- ---------- ------------ -----------
                   Grade 1                    Grade 2    Grade 3      Total
  CD68, Low        23 (40)                    16 (28)    18 (32)      57 (100)
  CD68, High       37 (22)                    73 (42)    62 (36)      172 (100)
  Total            60 (26)                    89 (39)    80 (35)      229 (100)
  Missing          20                                    Chi-Square   8.319
                                                         P-value      0.016
                   Grade 1                    Grade 2    Grade 3      Total
  M-CSF, Low       23 (41)                    18 (32)    15 (27)      56 (100)
  M-CSF, High      35 (21)                    67 (40)    67 (40)      169 (100)
  Total            58 (26)                    85 (38)    82 (37)      225 (100)
  Missing          24                                    Chi-Square   9.300
                                                         P-value      0.010
                   Grade 1                    Grade 2    Grade 3      Total
  TGF-beta, Low    15 (13)                    66 (56)    36 (31)      117 (100)
  TGF-beta, High   6 (5)                      71 (58)    45 (37)      122 (100)
  Total            21 (9)                     137 (57)   81 (34)      239 (100)
  Missing          10                                    Chi-Square   7.091
                                                         P-value      0.029

###### 

Results of expression of CD68 and M-CSF in tumor versus expression of Ki67 in patients with soft tissue sarcomas, N = 249

  **Expression**   **Ki67 (%)**                          
  ---------------- -------------- --------- ------------ -----------
  CD68, Low        15 (27)        19 (35)   21 (38)      55 (100)
  CD68, High       15 (9)         42 (25)   110 (66)     167 (100)
  Total            30 (14)        61 (28)   131 (59)     222 (100)
  Missing          27                       Chi-Square   16.947
                                            P-value      \<0.001
                   Low            Medium    High         Total
  M-CSF, Low       14 (26)        16 (30)   23 (43)      53 (100)
  M-CSF, High      15 (9)         41 (25)   108 (66)     164 (100)
  Total            29 (13)        57 (26)   131 (60)     217 (100)
  Missing          32                       Chi-Square   12.695
                                            P-value      0.002
                   Low            Medium    High         Total
  TGF-beta, Low    21 (18)        34 (30)   59 (52)      114 (100)
  TGF-beta, High   7 (6)          28 (25)   79 (69)      114 (100)
  Total            28 (12)        62 (27)   138 (31)     228 (100)
  Missing          21                       Chi-Square   10.749
                                            P-value      0.005

Multivariate analyses
---------------------

Significant demographic, clinicopathological, and expression variables from the univariate analyses were entered into the multivariate Cox regression analysis. In the multivariate analysis, the co-expression of M-CSF and TGF-beta in the tumor was an independent prognostic factor for DSS. Other independent negative prognostic variables were malignancy grade (P \< 0.001), metastasis at time of diagnosis (P \< 0.001) and non-wide resection margins (P = 0.001, Table [6](#T6){ref-type="table"}).

###### 

Results of Cox regression analysis summarizing significant independent prognostic factors in patients with soft tissue sarcomas

                                        **Tumor, N=249**   **Capsule, N=80**                                    
  ------------------------------------- ------------------ ------------------- --------- ------- -------------- ---------
  **Nationality**                                                                                                
   Norwegian                            1.000                                            1.000                   
   Russian                              0.948              0.603-1.490         0.816     0.588   0.263-1.312    0.194
  **Tumor size**                                                                                                 
   \< 5 cm                              1.000                                  0.540\*   1.000                  0.342\*
   5-10 cm                              1.103              0.687-1.770         0.685     0.888   0.376-2.099     
   \> 10 cm                             1.310              0.797-2.153         0.287     1.671   0.660-4.233     
  **Malignancy grade FNCLCC**                                                                                    
   1                                    1.000                                  0.001\*   1.000                  0.051\*
   2                                    1.997              1.129-3.531         0.017     1.402   0.383-5.137    0.610
   3                                    2.874              1.617-5.107         \<0.001   2.954   0.837-10.432   0.092
  **Metastasis at time of diagnosis**                                                                            
   No                                   1.000                                            1.000                   
   Yes                                  2.842              1.855-4.354         \<0.001   2.101   0.901-4.898    0.086
  **Resection margins**                                                                                          
   Wide                                 1.000                                            1.000                   
   Non-wide                             2.523              1.706-3.730         \<0.001   2.245   1.077-4-680    0.031
  **Ki67**                                                                                                       
   Low                                  1.000                                  0.432\*   1.000                   
   Medium                               1.059              0.528-2.163         0.876     \-      \-             \-
   High                                 1.365              0.710-2.625         0.351     2.553   1.167-5.584    0.019
  **M-CSF**                                                                                                      
   Low                                  1.000                                            NIA                     
   High                                 0.815              0.463-1.435         0.478                             
  **TGF-beta**                                                                                                   
   Low                                  1.000                                            NIA                     
   High                                 0.682              0.247-1.881         0.460                             
  **M-CSF and TGF-beta**                                                                                         
   Low                                  1.000                                            NIA                     
   High                                 1.532              1.062-2.208         0.022                             

\* Overall significance as a prognostic factor. NIA = Not included in analysis**.**

In patients with tissue from peritumoral capsule, independent negative prognostic variables were non-wide resection margins (P = 0.031) and high expression of Ki67 (P = 0.019, Table [6](#T6){ref-type="table"})

Discussion
==========

In this study we evaluated whether there is an association between the expression of CD57, CD68, M-CSF, CSF-1R, Ki67 and TGF-beta in tumors or peritumoral capsule and survival in 249 non-GIST STS patients. Increased co-expression of M-CSF and TGF-beta in the tumor and increased expression of Ki67 in the peritumoral capsule were independent negative prognostic factors for DSS in patients with STS. High expression of M-CSF in tumor was correlated with high malignancy grade, increased Ki67 and short DSS. To our knowledge, this is the first report on co-expression of M-CSF and TGF-beta in STS and the first evidence of its possible clinical relevance in STS patients.

STS have varying biological characteristics regardless of histological entities. Its prognosis is poor, but also difficult to predict. This aggressive behavior reflects, at least in part, the capacity of the tumor to evade host immune surveillance. Evasion strategies can protect cancer cells from immune responses by a variety of mechanisms including self-tolerance, sequestration of tissue from surveillance, antigen shedding, lymphocyte killing, secretion of immunosuppressive cytokines, lack of MHC II expression, lack of co-stimulatory molecules and local secretion of prostaglandins.

CD57 positive cells have been implicated in the resistance against malignant and virally-infected cells. Presence of these cells was observed to be an independent prognostic marker for a better DSS in squamous cell carcinoma \[[@B31]\] and adenocarcinoma \[[@B32]\] of the lung, as well as in other cancers such as colonic and gastric carcinomas \[[@B14],[@B15]\]. In NSCLS, high density of stromal CD57 positive cells was an independent, positive prognostic factor for DSS, whereas high density of CD57 positive cells within neoplastic cell areas was not \[[@B33]\]. In our material there was no such correlation in tumor or peritumoral capsule. The location of infiltrating lymphocytes may be important. There are major differences between 1) inflammatory cells within cancer cell nests in carcinomas (epithelial CD57 positive cells); 2) inflammatory cells present in the stroma of epithelial tumors (stromal CD57 positive cells), 3) inflammatory cells present along the invasive margins (peritumoral CD57 positive cells); and, 4) inflammatory cells in the peritumoral capsule of stromal tumors such as STS.

In addition to NK-cells, expression of CD57 is also found on T-lineage lymphocytes, where it is currently considered a marker-replicative senescence ("clonal exhaustion"), i.e., a high susceptibility to activation-induced cell death and the inability to undergo new cell-division cycles despite preserved ability to secrete cytokines upon encounter with their cognate antigen \[[@B34]\]. Even on NK cells it does not constitute a one-marker-labels-all solution: CD57 defines a functionally distinct population of mature NK cells in the human CD56dim CD16+ NK-cell subset \[[@B35]\].

Studies have demonstrated a close association between M-CSF and tumor progression in lung cancer cell lines \[[@B36]\]. In a NSCLC cohort studied by Kaminska et al. \[[@B37]\], high pretreatment serum levels of M-CSF were an independent predictor of poor survival in these patients. However, Al-Shibli et al. \[[@B33]\] did not find any correlation between expression of M-CSF in NSCLC and DSS. CSF-1 protected osteoclasts from suppressive effects of transforming growth factor beta (TGF-beta) in a mouse mammary tumor cell line \[[@B38]\]. Kirma et al. studied M-CSF and TGF-beta in cervical cancer and found that CSF-1R (c-fms proto-oncogene product) activation may play a role in cervical carcinogenesis \[[@B39]\]. Richardsen et al. \[[@B27]\] showed that high M-CSF expression was correlated with a high malignancy grade in STS. In our study, high M-CSF expression in tumor correlated with a high malignancy grade, increased Ki67 and DSS in univariate analyses. But the expression of M-CSF in peritumoral capsule showed no correlation with DSS.

TGF-beta is a multifunctional cytokine known to induce G1 arrest in order to end proliferation, induce differentiation, or promote apoptosis in normal cells, thus being a natural tumor-suppressive agent. Though in tumorigenesis this mediator initiates EMT through activation of Smad and non-Smad signalling pathways\[[@B40]\]. Such pro-neoplastic action becomes possible through either blockade of the TGF-beta pathway with receptor-inactivating mutations, or selective inactivation of the tumor-inhibiting arm of this pathway\[[@B41]\]. High TGF-beta expression was an independent negative prognostic factor for disease specific survival in STS\[[@B42]\]. In the multivariate analysis, co-expression of M-CSF and TGF-beta were an even stronger negative prognostic factor in this study. We found a co-variation of expression of M-CSF and TGF-beta in tumor. TFG-beta might regulate the expression of M-CSF. Grayfer et al. reported on the regulation of pro-inflammatory functions of goldfish macrophages and induction of gene expression by recombinant goldfish CSF-1 (rgCSF-1). At 72 h post treatment rgCSF-1 increased the expression of TGF-beta \[[@B43]\]. The combined expression of immunostimulatory granulocyte macrophage colony stimulating factor (GM-CSF) and antitumor suppressor TGF-β2 antisense (AS) transgenes can break tolerance and stimulate immune responses to cancer-associated antigens which make it possible to design bifunctional therapeutic anti-cancer vaccines\[[@B44]\].

Increased expression of Ki67 and M-CSF in tumor are negative prognostic indicators for patients with STS, but this is not independent of malignancy grade. In the univariate analysis presented TGF-beta seems to be the dominating factor, while low or high M-CSF expression in combination with low TGF-beta expression does not seem to influence prognosis significantly. Both expression of TGF-beta and M-CSF have co-variation with malignancy grade and expression of Ki67. In the multivariate analysis the co-expression of M-CSF and TGF-beta was a stronger prognosticator for DSS than each of the markers alone. Expression of Ki67 in tumor was not an independent prognosticator. As mitotic activity is one of the criteria determining the malignancy grade, expression of Ki67 is closely correlated to mitotic activity, hence also malignancy grade \[[@B45]\]. Archad et al. found that malignancy grade is a more important prognostic factor in glial neoplasms than Ki67 \[[@B19]\]. So Ki67 may not provide additional information if the tumor malignancy grade is classified correctly. The tumor stroma is important for cancer progression \[[@B46]\]. There is no evaluation of tumor stroma in the grading systems of STS. But Ki67 expression in the peritumoral capsule may have prognostic impact in addition to malignancy grading of the tumor. Further research is needed to determine whether an increased expression of Ki67 may be the result of on increased migration of fast-proliferating cells in the peritumoral capsule or an enhanced proliferation effect of tumor-released cytokines on the stromal cells.

Conclusion
==========

In summary, increased co-expression of M-CSF and TGF-beta in tumor and increased Ki67 expression in the peritumoral capsule of STS patients were independent negative prognostic factors for DSS. This data may provide additional information to guide therapy after surgical resection.
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